James A Martenson

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. pmc Phase III, double-blind study of depot octreotide versus placebo in the prevention of acute diarrhea in patients receiving pelvic radiation therapy: results of North Central Cancer Treatment Group N00CA
    James A Martenson
    Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 26:5248-53. 2008
  2. ncbi request reprint Phase III study of adjuvant chemotherapy and radiation therapy compared with chemotherapy alone in the surgical adjuvant treatment of colon cancer: results of intergroup protocol 0130
    James A Martenson
    North Central Cancer Treatment Group, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 22:3277-83. 2004
  3. ncbi request reprint Acute diarrhea during adjuvant therapy for rectal cancer: a detailed analysis from a randomized intergroup trial
    Robert C Miller
    North Central Cancer Treatment Group, Coordinating Center, Rochester, MN, USA
    Int J Radiat Oncol Biol Phys 54:409-13. 2002
  4. pmc Comparison of provider-assessed and patient-reported outcome measures of acute skin toxicity during a Phase III trial of mometasone cream versus placebo during breast radiotherapy: the North Central Cancer Treatment Group (N06C4)
    Michelle A Neben-Wittich
    Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Int J Radiat Oncol Biol Phys 81:397-402. 2011
  5. ncbi request reprint Paclitaxel, carboplatin, 5-fluorouracil, and radiation for locally advanced esophageal cancer: phase II results of preliminary pharmacologic and molecular efforts to mitigate toxicity and predict outcomes: North Central Cancer Treatment Group (N0044)
    Aminah Jatoi
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Am J Clin Oncol 30:507-13. 2007
  6. ncbi request reprint Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942
    Michael G Haddock
    Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 25:2567-72. 2007
  7. ncbi request reprint Phase III double-blind study of glutamine versus placebo for the prevention of acute diarrhea in patients receiving pelvic radiation therapy
    Timothy F Kozelsky
    Mayo Clinic, 200 First St, SW, Rochester, MN 55905, USA
    J Clin Oncol 21:1669-74. 2003
  8. doi request reprint Assessment of patient-reported measures of bowel function before and after pelvic radiotherapy: an ancillary study of the North Central Cancer Treatment Group study N00CA
    Pamela J Atherton
    Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA
    Support Care Cancer 21:1193-9. 2013
  9. doi request reprint Predictors of pretransplant dropout and posttransplant recurrence in patients with perihilar cholangiocarcinoma
    Sarwa Darwish Murad
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
    Hepatology 56:972-81. 2012
  10. ncbi request reprint A phase I study of radiation therapy and twice-weekly gemcitabine and cisplatin in patients with locally advanced pancreatic cancer
    James A Martenson
    Mayo Clinic, Rochester, MN 55905, USA
    Int J Radiat Oncol Biol Phys 55:1305-10. 2003

Collaborators

Detail Information

Publications25

  1. pmc Phase III, double-blind study of depot octreotide versus placebo in the prevention of acute diarrhea in patients receiving pelvic radiation therapy: results of North Central Cancer Treatment Group N00CA
    James A Martenson
    Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 26:5248-53. 2008
    ..To assess the effectiveness of depot octreotide for the prevention of diarrhea during pelvic radiation therapy...
  2. ncbi request reprint Phase III study of adjuvant chemotherapy and radiation therapy compared with chemotherapy alone in the surgical adjuvant treatment of colon cancer: results of intergroup protocol 0130
    James A Martenson
    North Central Cancer Treatment Group, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 22:3277-83. 2004
    ..Some patients with colon cancer have a high risk of local recurrence postoperatively. This trial was undertaken to determine whether radiation therapy added to an adjuvant chemotherapy regimen improves outcome in high-risk patients...
  3. ncbi request reprint Acute diarrhea during adjuvant therapy for rectal cancer: a detailed analysis from a randomized intergroup trial
    Robert C Miller
    North Central Cancer Treatment Group, Coordinating Center, Rochester, MN, USA
    Int J Radiat Oncol Biol Phys 54:409-13. 2002
    ..Toxicity from a previously reported randomized clinical trial was analyzed to quantify the difference in this risk. Additionally, the persistence of diarrhea after RT was analyzed...
  4. pmc Comparison of provider-assessed and patient-reported outcome measures of acute skin toxicity during a Phase III trial of mometasone cream versus placebo during breast radiotherapy: the North Central Cancer Treatment Group (N06C4)
    Michelle A Neben-Wittich
    Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Int J Radiat Oncol Biol Phys 81:397-402. 2011
    ..However, prospectively planned secondary analyses of patient-reported outcomes (PROs), using the Skindex-16 and Skin Toxicity Assessment Tool (STAT), were positive. This study assesses the relationship between PA outcomes and PROs...
  5. ncbi request reprint Paclitaxel, carboplatin, 5-fluorouracil, and radiation for locally advanced esophageal cancer: phase II results of preliminary pharmacologic and molecular efforts to mitigate toxicity and predict outcomes: North Central Cancer Treatment Group (N0044)
    Aminah Jatoi
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Am J Clin Oncol 30:507-13. 2007
    ..This study tested a 3-drug, multimodality approach. Chemotherapy dose reductions, the addition of amifostine, and pharmacogenetics were tested in an effort to mitigate toxicity and predict outcomes...
  6. ncbi request reprint Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942
    Michael G Haddock
    Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 25:2567-72. 2007
    ..A phase II study was conducted to determine the efficacy and toxicity of radiotherapy with concomitant gemcitabine and cisplatin for patients with locally advanced pancreatic adenocarcinoma...
  7. ncbi request reprint Phase III double-blind study of glutamine versus placebo for the prevention of acute diarrhea in patients receiving pelvic radiation therapy
    Timothy F Kozelsky
    Mayo Clinic, 200 First St, SW, Rochester, MN 55905, USA
    J Clin Oncol 21:1669-74. 2003
    ....
  8. doi request reprint Assessment of patient-reported measures of bowel function before and after pelvic radiotherapy: an ancillary study of the North Central Cancer Treatment Group study N00CA
    Pamela J Atherton
    Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA
    Support Care Cancer 21:1193-9. 2013
    ..The Bowel Function Questionnaire (BFQ) has been used in clinical trials to assess symptoms during and after pelvic radiotherapy (RT). This study evaluated the importance of symptoms in the BFQ from a patient perspective...
  9. doi request reprint Predictors of pretransplant dropout and posttransplant recurrence in patients with perihilar cholangiocarcinoma
    Sarwa Darwish Murad
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
    Hepatology 56:972-81. 2012
    ..8; P = 0.01), portal vein encasement (HR 3.3; P = 0.007), and residual tumor on explant (HR 9.8; P < 0.001). Primary sclerosing cholangitis (PSC), age, history of cholecystectomy, and waiting time were not independent predictors...
  10. ncbi request reprint A phase I study of radiation therapy and twice-weekly gemcitabine and cisplatin in patients with locally advanced pancreatic cancer
    James A Martenson
    Mayo Clinic, Rochester, MN 55905, USA
    Int J Radiat Oncol Biol Phys 55:1305-10. 2003
    ..Gemcitabine's radiosensitizing properties can theoretically be exploited by twice-weekly administration. This study assessed toxicity in patients with pancreatic cancer treated with radiation therapy, gemcitabine, and cisplatin...
  11. ncbi request reprint Treatment options for hepatobiliary and pancreatic cancer
    Steven R Alberts
    Division of Medical Oncology, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 82:628-37. 2007
    ..For pancreatic cancer, surgery, radiation, and systemic therapy all have potential roles. This review provides an updated summary of diagnosis and assessment together with treatment options for this group of cancers...
  12. pmc Long-term follow-up of a Phase II trial of high-dose radiation with concurrent 5-fluorouracil and cisplatin in patients with anal cancer (ECOG E4292)
    A Bapsi Chakravarthy
    Department of Radiation Oncology, Vanderbilt University Medical Center, 2220 Pierce Avenue, Preston Research Building, Room B 1003, Nashville, TN 37232, USA
    Int J Radiat Oncol Biol Phys 81:e607-13. 2011
    ..This Phase II clinical trial was performed to determine whether cisplatin could replace MMC in the treatment of anal cancer...
  13. pmc Assessment of long-term rectal function in patients who received pelvic radiotherapy: a pooled North Central Cancer Treatment Group trial analysis, N09C1
    Lindsay C Brown
    Department of Radiation Oncology, Mayo Clinic, 200 First St SW, Rochester, MN, 55905, USA
    Support Care Cancer 21:2869-77. 2013
    ..Pelvic radiotherapy (PRT) is known to adversely affect bowel function (BF) and patient well-being. This study characterized long-term BF and evaluated quality of life (QOL) in patients receiving PRT...
  14. ncbi request reprint Patient assessment of bowel function during and after pelvic radiotherapy: results of a prospective phase III North Central Cancer Treatment Group clinical trial
    Michael G Haddock
    Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 25:1255-9. 2007
    ..To evaluate patient assessment of long-term effect of pelvic radiotherapy on bowel function...
  15. ncbi request reprint Endocavitary radiation therapy for rectal adenocarcinoma: 10-year results
    Sophie Lavertu
    Division of Radiation Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Clin Oncol 26:508-12. 2003
    ..In conclusion, radiation therapy resulted in a local control rate of 76% at 10 years in curatively treated patients. Although most patients experience toxicity from this treatment, loss of sphincter function is rare...
  16. pmc Mometasone furoate effect on acute skin toxicity in breast cancer patients receiving radiotherapy: a phase III double-blind, randomized trial from the North Central Cancer Treatment Group N06C4
    Robert C Miller
    Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Int J Radiat Oncol Biol Phys 79:1460-6. 2011
    ..A two-arm, double-blind, randomized trial was performed to evaluate the effect of 0.1% mometasone furoate (MMF) on acute skin-related toxicity in patients undergoing breast or chest wall radiotherapy...
  17. ncbi request reprint Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis
    Leonard L Gunderson
    Radiation Oncology Department, Mayo Clinic Cancer Center, Scottsdale, AZ 85259, USA
    J Clin Oncol 22:1785-96. 2004
    ..To determine survival and relapse rates by T and N stage and treatment method in five randomized phase III North American rectal adjuvant studies...
  18. ncbi request reprint Efficacy and treatment-related toxicity of radiotherapy for early-stage primary non-Hodgkin lymphoma of the parotid gland
    Kenneth R Olivier
    Division of Radiation Oncology, Mayo Clinic, Rochester, MN, USA
    Int J Radiat Oncol Biol Phys 60:1510-4. 2004
    ..To assess the efficacy of radiotherapy (RT) in the treatment of primary non-Hodgkin lymphoma (NHL) of the parotid gland...
  19. doi request reprint A pilot study examining circulating interleukin-6 and transforming growth factor-β levels during pelvic radiation therapy
    Christopher L Hallemeier
    Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Am J Clin Oncol 36:344-7. 2013
    ..To determine if circulating levels of the inflammatory cytokines interleukin-6 (IL-6) and transforming growth factor-β (TGF-β levels) are elevated during pelvic radiotherapy (RT)...
  20. ncbi request reprint Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer: a pooled analysis
    Leonard L Gunderson
    Department of Radiation Oncology, Mayo Clinic Scottsdale, Scottsdale, AZ 85259, USA
    Int J Radiat Oncol Biol Phys 54:386-96. 2002
    ..To determine the rates of survival and disease control by TNM and MAC stage in three randomized North American rectal adjuvant studies...
  21. ncbi request reprint Safety and efficacy of external beam radiation therapy for non-Hodgkin lymphoma in patients with prior 90Y-ibritumomab tiuxetan radioimmunotherapy
    Terry E Justice
    Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 107:433-8. 2006
    ..Many patients eventually relapse after radioimmunotherapy (RIT) and require additional treatment. The goal of this study was to determine the safety and efficacy of external beam radiation therapy (EBRT) delivered after RIT...
  22. ncbi request reprint Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144
    Stephen R Smalley
    Kansas City Community Clinical Oncology Program CCOP, Kansas City, KS, USA
    J Clin Oncol 24:3542-7. 2006
    ..Adjuvant chemoradiotherapy after or before resection of high-risk rectal cancer improves overall survival (OS) and pelvic control. We studied three postoperative fluorouracil (FU) radiochemotherapy regimens...
  23. ncbi request reprint Gastric surgical adjuvant radiotherapy consensus report: rationale and treatment implementation
    Stephen R Smalley
    Radiation Oncology Center of Olathe, Olathe, KS 66061, USA
    Int J Radiat Oncol Biol Phys 52:283-93. 2002
    ..Supportive therapy during and after radiochemotherapy is also discussed...
  24. ncbi request reprint Recommended guidelines for the treatment of cancer treatment-induced diarrhea
    Al B Benson
    Robert H Lurie Comprehensive Cancer Center of Northwestern University, 676 N St Clair, Suite 850, Chicago, IL 60611, USA
    J Clin Oncol 22:2918-26. 2004
    ..To update and expand on previously published clinical practice guidelines for the treatment of cancer treatment-induced diarrhea...
  25. ncbi request reprint Keratinocyte growth factor: not yet ready for prime time
    Charles L Loprinzi
    J Clin Oncol 21:1429-30. 2003